

# Diana O Perkins

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2105749/diana-o-perkins-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162  
papers

16,837  
citations

45  
h-index

129  
g-index

166  
ext. papers

19,719  
ext. citations

5.7  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
162	Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort.. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2022</b> , 1	4.5	0
161	The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium.. <i>Schizophrenia Research</i> , <b>2022</b> , 241, 1-9	3.6	0
160	Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes.. <i>Psychological Medicine</i> , <b>2022</b> , 1-8	6.9	0
159	Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis. <i>Schizophrenia Research: Cognition</i> , <b>2022</b> , 27, 100225	2.8	
158	A greedy regression algorithm with coarse weights offers novel advantages.. <i>Scientific Reports</i> , <b>2022</b> , 12, 5440	4.9	
157	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. <i>Nature</i> , <b>2022</b> ,	50.4	35
156	The use of diary methods to evaluate daily experiences in first-episode psychosis.. <i>Psychiatry Research</i> , <b>2022</b> , 312, 114548	9.9	0
155	Family history of psychosis in youth at clinical high risk: A replication study.. <i>Psychiatry Research</i> , <b>2022</b> , 311, 114480	9.9	0
154	Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis. <i>Psychiatric Research and Clinical Practice</i> , <b>2021</b> , 3, 163-171	2.7	1
153	Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. <i>Schizophrenia Research</i> , <b>2021</b> , 238, 137-144	3.6	1
152	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. <i>Schizophrenia Research</i> , <b>2021</b> , 230, 26-37	3.6	0
151	Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2021</b> , 7, 171-174	2.4	1
150	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. <i>Biological Psychiatry</i> , <b>2021</b> , 90, 632-642	7.9	8
149	Cross-paradigm connectivity: reliability, stability, and utility. <i>Brain Imaging and Behavior</i> , <b>2021</b> , 15, 614-629	4.1	2
148	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 10-17	3.6	17
147	Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. <i>Microbial Biotechnology</i> , <b>2021</b> , 15, 96-103	3.3	5
146	Depression: An actionable outcome for those at clinical high-risk. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 38-43	3.6	4

145	Social decline in the psychosis prodrome: Predictor potential and heterogeneity of outcome. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 44-51	3.6	6
144	Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 72-77	3.6	2
143	Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 95-100	3.6	6
142	Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis. <i>NeuroImage: Clinical</i> , <b>2021</b> , 31, 102757	5.3	1
141	Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 591127	5	2
140	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	3
139	Enhancing stress reactivity and wellbeing in early schizophrenia: A randomized controlled trial of Integrated Coping Awareness Therapy (I-CAT). <i>Schizophrenia Research</i> , <b>2021</b> , 235, 91-101	3.6	2
138	Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	1
137	Clinician Recognition of First Episode Psychosis. <i>Journal of Adolescent Health</i> , <b>2021</b> , 69, 457-464	5.8	
136	Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up. <i>Schizophrenia Research</i> , <b>2021</b> , 236, 87-88	3.6	0
135	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2021</b> , 56, 943-952	4.5	0
134	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 80	8.6	3
133	Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 2899-2909	4.3	3
132	Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. <i>Psychoneuroendocrinology</i> , <b>2020</b> , 115, 104649	5	11
131	Potential Roles of Redox Dysregulation in the Development of Schizophrenia. <i>Biological Psychiatry</i> , <b>2020</b> , 88, 326-336	7.9	29
130	Stability of mismatch negativity event-related potentials in a multisite study. <i>International Journal of Methods in Psychiatric Research</i> , <b>2020</b> , 29, e1819	4.3	5
129	Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis. <i>Journal of Abnormal Psychology</i> , <b>2020</b> , 129, 599-611	7	3
128	Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 155-163	11.9	45

127	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. <i>Schizophrenia Research</i> , <b>2020</b> , 216, 184-191	3.6	12
126	Duration of the psychosis prodrome. <i>Schizophrenia Research</i> , <b>2020</b> , 216, 443-449	3.6	5
125	Progressive reconfiguration of resting-state brain networks as psychosis develops: Preliminary results from the North American Prodrome Longitudinal Study (NAPLS) consortium. <i>Schizophrenia Research</i> , <b>2020</b> , 226, 30-37	3.6	14
124	Stress perception following childhood adversity: Unique associations with adversity type and sex. <i>Development and Psychopathology</i> , <b>2020</b> , 32, 343-356	4.3	9
123	Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 164-171	11.9	19
122	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 2455-2467	15.1	41
121	Common Data Elements for National Institute of Mental Health-Funded Translational Early Psychosis Research. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2020</b> , 5, 10-22	3.4	2
120	North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. <i>Schizophrenia Research</i> , <b>2020</b> ,	3.6	14
119	Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101862	5.3	26
118	Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. <i>Schizophrenia Research</i> , <b>2019</b> , 213, 48-55	3.6	10
117	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 311-319	3.6	17
116	Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1187-1197	14.5	30
115	Recommendations and Challenges of the Clinical Services Panel of the PhenX Early Psychosis Working Group. <i>Psychiatric Services</i> , <b>2019</b> , 70, 514-517	3.3	5
114	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. <i>Psychiatry Research</i> , <b>2019</b> , 282, 112492	9.9	14
113	Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	1
112	The Early Psychosis Screener for Internet (EPSI)-SR: Predicting 12 month psychotic conversion using machine learning. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 390-396	3.6	9
111	Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 41-43	3.6	8
110	Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	5

109	Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. <i>Psychological Medicine</i> , <b>2019</b> , 49, 1670-1677	6.9	44
108	Altered Brain Activation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 924-933	1.3	12
107	Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. <i>Biological Psychiatry</i> , <b>2019</b> , 86, 110-119	7.9	20
106	The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 763-772	1.3	28
105	Tobacco use and psychosis risk in persons at clinical high risk. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 1173-1181	3.1	6
104	Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 76, 268-274	16.6	32
103	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 96-103	3.6	21
102	The role of a family history of psychosis for youth at clinical high risk of psychosis. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 251-256	3.3	7
101	Changes in symptom content from a clinical high-risk state to conversion to psychosis. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 257-263	3.3	4
100	Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms. <i>Cerebral Cortex</i> , <b>2019</b> , 29, 1263-1279	5.1	25
99	The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 516-521	3.6	7
98	Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 254-263	1.3	38
97	Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 522-530	3.6	14
96	The Early Psychosis Screener (EPS): Item development and qualitative validation. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 504-508	3.6	8
95	Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. <i>Journal of Clinical Child and Adolescent Psychology</i> , <b>2018</b> , 47, 69-78	5.4	14
94	Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. <i>Schizophrenia Research</i> , <b>2018</b> , 192, 357-363	3.6	32
93	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 286-296	1.3	21
92	Exploration of clinical high-risk dropouts. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 579-580	3.6	10

91	Enhancing stress reactivity and wellbeing in early schizophrenia: A pilot study of individual coping awareness therapy (I-CAT). <i>Schizophrenia Research</i> , <b>2018</b> , 201, 413-414	3.6	6
90	Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. <i>Schizophrenia Research</i> , <b>2018</b> , 201, 130-136	3.6	11
89	Networks of blood proteins in the neuroimmunology of schizophrenia. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 112	8.6	13
88	Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. <i>Nature Communications</i> , <b>2018</b> , 9, 3836	17.4	83
87	Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at Clinically High Risk. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 960-968	14.5	61
86	Anxiety in youth at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , <b>2017</b> , 11, 480-487	3.3	43
85	Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. <i>Schizophrenia Research</i> , <b>2017</b> , 189, 169-174	3.6	22
84	The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 2188-2195	8.7	8
83	Multisite reliability of MR-based functional connectivity. <i>NeuroImage</i> , <b>2017</b> , 146, 959-970	7.9	83
82	Comorbid diagnoses for youth at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2017</b> , 190, 90-95	3.6	65
81	Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. <i>Psychiatry Research</i> , <b>2017</b> , 258, 462-468	9.9	3
80	Evidence that endogenous formaldehyde produces immunogenic and atherogenic adduct epitopes. <i>Scientific Reports</i> , <b>2017</b> , 7, 10787	4.9	13
79	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 57-63	1.3	62
78	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , <b>2017</b> , 49, 27-35	36.3	530
77	Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e1431	4.6	1
76	Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 1239-1248	14.5	158
75	Reproducibility and Visual Inspection of Data. <i>Biological Psychiatry</i> , <b>2016</b> , 80, e33-5	7.9	2
74	The Violent Content in Attenuated Psychotic Symptoms. <i>Psychiatry Research</i> , <b>2016</b> , 242, 61-66	9.9	10

73	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 3-9	2.9	5
72	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 732-43	1.3	144
71	Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. <i>Schizophrenia Research</i> , <b>2016</b> , 171, 176-81	3.6	41
70	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. <i>Schizophrenia Research</i> , <b>2016</b> , 172, 106-13	3.6	18
69	Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2016</b> , 51, 497-503	4.5	43
68	An Individualized Risk Calculator for Research in Prodromal Psychosis. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 980-988	11.9	332
67	The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. <i>Schizophrenia Research</i> , <b>2016</b> , 172, 29-34	3.6	8
66	Traumatic brain injury in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 77-81	3.6	8
65	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1234-42	1.3	15
64	Theory of Mind, Emotion Recognition and Social Perception in Individuals at Clinical High Risk for Psychosis: findings from the NAPLS-2 cohort. <i>Schizophrenia Research: Cognition</i> , <b>2015</b> , 2, 133-139	2.8	36
63	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 2558-79	5.9	49
62	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 882-91	14.5	199
61	Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1066-75	1.3	59
60	Severity of thought disorder predicts psychosis in persons at clinical high-risk. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 169-177	3.6	36
59	Patterns of premorbid functioning in individuals at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 209-213	3.6	17
58	Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 147-57	7.9	384
57	Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 419-28	1.3	148
56	At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , <b>2015</b> , 14, 322-32	14.4	172

55	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. <i>BMC Psychiatry</i> , <b>2015</b> , 15, 276	4.2	10
54	Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. <i>Microbial Biotechnology</i> , <b>2015</b> , 9, 467-75	3.3	22
53	Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic Disorders. <i>Molecular Neuropsychiatry</i> , <b>2015</b> , 1, 13-22	4.9	22
52	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. <i>Psychiatry Research</i> , <b>2015</b> , 230, 878-84	9.9	10
51	Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. <i>Psychiatry Research</i> , <b>2014</b> , 215, 52-60	9.9	16
50	Stress exposure and sensitivity in the clinical high-risk syndrome: initial findings from the North American Prodrome Longitudinal Study (NAPLS). <i>Schizophrenia Research</i> , <b>2014</b> , 160, 104-9	3.6	50
49	Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 263-6	3.6	34
48	Current status specifiers for patients at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 158, 69-75	3.6	34
47	The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. <i>Psychiatry Research</i> , <b>2014</b> , 219, 506-12	9.9	15
46	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , <b>2014</b> , 218, 39-43	9.9	10
45	The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 1452-61	1.3	117
44	Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 156, 277-80	3.6	29
43	Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 410-7	7.9	157
42	Early traumatic experiences in those at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , <b>2013</b> , 7, 300-5	3.3	81
41	Theory of mind and social judgments in people at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 498-504	3.6	29
40	Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. <i>Schizophrenia Research</i> , <b>2013</b> , 148, 99-104	3.6	30
39	North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. <i>Schizophrenia Research</i> , <b>2012</b> , 142, 77-82	3.6	188
38	Nuclear and cytoplasmic localization of neural stem cell microRNAs. <i>Rna</i> , <b>2011</b> , 17, 675-86	5.8	89



37	Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. <i>Microbial Biotechnology</i> , <b>2010</b> , 4, 220-6	3.3	40
36	Additional layers of gene regulatory complexity from recently discovered microRNA mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2010</b> , 42, 1236-42	5.6	12
35	The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. <i>Schizophrenia Research</i> , <b>2009</b> , 115, 50-7	3.6	52
34	Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 894-908	1.3	327
33	Facial affect recognition in individuals at clinical high risk for psychosis. <i>British Journal of Psychiatry</i> , <b>2008</b> , 192, 67-8	5.4	145
32	Assessment of social judgments and complex mental states in the early phases of psychosis. <i>Schizophrenia Research</i> , <b>2008</b> , 100, 237-41	3.6	59
31	Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. <i>Archives of General Psychiatry</i> , <b>2008</b> , 65, 28-37		1004
30	miRNA and Schizophrenia <b>2008</b> , 267-281		
29	Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 106-13	4.6	163
28	North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 665-72	1.3	231
27	Neuroprotection: A New Strategy in the Treatment of Schizophrenia. <i>CNS Spectrums</i> , <b>2007</b> , 12, 1-16	1.8	20
26	Early Identification and Treatment of Schizophrenia. <i>CNS Spectrums</i> , <b>2007</b> , 12, 5-8	1.8	
25	Emotion perception and social skill over the course of psychosis: a comparison of individuals "at-risk" for psychosis and individuals with early and chronic schizophrenia spectrum illness. <i>Cognitive Neuropsychiatry</i> , <b>2007</b> , 12, 198-212	2	150
24	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. <i>Genome Biology</i> , <b>2007</b> , 8, R27	18.3	420
23	Systematic discovery of the grammar of translational inhibition by RNA hairpins. <i>Journal of Theoretical Biology</i> , <b>2006</b> , 241, 205-15	2.3	2
22	What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 35-39		
21	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. <i>Schizophrenia Research</i> , <b>2006</b> , 83, 53-63	3.6	120
20	Clinical trials in schizophrenia with results for the real world. <i>CNS Spectrums</i> , <b>2006</b> , 11, 9-13	1.8	8

19	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1209-23	59.2	4423
18	Expanding the Central dogma: the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. <i>Molecular Psychiatry</i> , <b>2005</b> , 10, 69-78	15.1	76
17	Evaluating and treating the prodromal stage of schizophrenia. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2005</b> , 3, 79-85		
16	Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 1785-804	11.9	896
15	Evaluating and treating the prodromal stage of schizophrenia. <i>Current Psychiatry Reports</i> , <b>2004</b> , 6, 289-95	1	13
14	Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 404-9	1.7	52
13	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. <i>British Journal of Psychiatry</i> , <b>2004</b> , 185, 18-24	5.4	120
12	Practice guideline for the treatment of patients with schizophrenia, second edition. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1-56	11.9	855
11	Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 703-15	1.3	1175
10	Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 33-43	1.3	91
9	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. <i>Biological Psychiatry</i> , <b>2003</b> , 54, 453-64	7.9	161
8	Predictors of noncompliance in patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 1121-8	4.6	373
7	The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 884-97	7.9	414
6	Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. <i>Schizophrenia Research</i> , <b>2000</b> , 44, 1-10	3.6	139
5	Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. <i>Biological Psychiatry</i> , <b>2000</b> , 47, 762-6	7.9	90
4	Markers for schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1527; author reply 1528	11.9	2
3	The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. <i>Schizophrenia Bulletin</i> , <b>1999</b> , 25, 201-22	1.3	563
2	Personality disorder in HIV infection. <i>International Review of Psychiatry</i> , <b>1996</b> , 8, 253-258	3.6	14

- 1 Longitudinal study of social support and social conflict as predictors of depression and dysphoria among HIV-positive and HTV-negative gay men. *Depression*, **1994**, 2, 189-199